Does REGORAFENIB Cause Hyperkeratosis? 136 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 136 reports of Hyperkeratosis have been filed in association with REGORAFENIB (Stivarga). This represents 1.4% of all adverse event reports for REGORAFENIB.
136
Reports of Hyperkeratosis with REGORAFENIB
1.4%
of all REGORAFENIB reports
5
Deaths
35
Hospitalizations
How Dangerous Is Hyperkeratosis From REGORAFENIB?
Of the 136 reports, 5 (3.7%) resulted in death, 35 (25.7%) required hospitalization, and 1 (0.7%) were considered life-threatening.
Is Hyperkeratosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REGORAFENIB. However, 136 reports have been filed with the FAERS database.
What Other Side Effects Does REGORAFENIB Cause?
Off label use (1,906)
Fatigue (1,530)
Palmar-plantar erythrodysaesthesia syndrome (1,230)
Diarrhoea (1,221)
Decreased appetite (941)
Asthenia (825)
Death (813)
Dysphonia (702)
Nausea (688)
Pain in extremity (686)
What Other Drugs Cause Hyperkeratosis?
CABOZANTINIB S-MALATE (411)
ADALIMUMAB (332)
SUNITINIB MALATE (170)
ETANERCEPT (168)
SORAFENIB (150)
METHOTREXATE (149)
VEMURAFENIB (145)
RIPRETINIB (124)
RITUXIMAB (121)
TOCILIZUMAB (103)
Which REGORAFENIB Alternatives Have Lower Hyperkeratosis Risk?
REGORAFENIB vs REGORAFENIB\REGORAFENIB
REGORAFENIB vs RELATLIMAB
REGORAFENIB vs RELPAX
REGORAFENIB vs RELUGOLIX
REGORAFENIB vs REMDESIVIR